SANUWAVE Health, Inc. (OTC:SNWV) is a company that focuses on developing and commercializing non-invasive, biological response-activating devices. These devices are primarily used in the healthcare sector to treat chronic conditions and aid in wound healing. The company operates in a competitive landscape with peers like Rafarma Pharmaceuticals, Pressure BioSciences, GulfSlope Energy, TSS, and Aspen Group.
In evaluating SANUWAVE's financial performance, the Return on Invested Capital (ROIC) is a key metric. SNWV boasts a ROIC of 54.33%, which is significantly higher than its Weighted Average Cost of Capital (WACC) of 15.85%. This results in a ROIC to WACC ratio of 3.43, indicating that the company is generating substantial returns on its invested capital relative to its cost.
Comparatively, TSS, Inc. (TSSI) has the second-highest ROIC to WACC ratio of 2.02 among the peers. This suggests that TSSI is also efficiently generating returns over its cost of capital, though not as effectively as SNWV. TSSI's ROIC of 23.21% and WACC of 11.51% reflect a positive balance between returns and costs.
On the other hand, Pressure BioSciences, Inc. (PBIO) and Rafarma Pharmaceuticals, Inc. (RAFA) show lower efficiency. PBIO's ROIC of 42.55% is overshadowed by a high WACC of 67.83%, resulting in a ROIC to WACC ratio of 0.63. Similarly, RAFA's ROIC of 3.03% and WACC of 5.49% yield a ratio of 0.55, indicating less effective capital utilization.
GulfSlope Energy, Inc. (GSPE) and Aspen Group, Inc. (ASPU) present concerning figures with negative ROIC to WACC ratios. GSPE's ROIC of -1932.28% against a WACC of 5.71% results in a ratio of -338.65, while ASPU's ROIC of -4.51% and WACC of 17.88% lead to a ratio of -0.25. These negative ratios suggest that both companies are not covering their cost of capital, which could be a red flag for potential investors.
